Mezzion Pharma Co. Ltd. (140410.KQ), and Mezzion Pharmaceuticals Inc. (individually or collectively, "Mezzion") announced that Bill Breitenbach has joined Mezzion as the Chief Commercial Officer (CCO) effective June 1st, 2021. As CCO, Bill will be responsible for the management and oversight of all global commercial operations, including the planning, recruiting, and development of the leadership team, and for overseeing the pre-launch preparations and launch of UDENAFIL in selected major markets for the treatment of SVHD patients who have undergone Fontan surgical palliation. Mr. Breitenbach comes to Mezzion following a distinguished and lengthy career at Novo Nordisk and elsewhere during which he coordinated and oversaw five product launches in the USA and was associated with seven others. Amongst his achievements and under his management, Levemir® and Levemir® Flex Touch device® sales were driven to $1.9 billion in annual sales.